According to the offshore protein announcement, the daily closing price increase deviation value of the company's stock exceeded 30% during the 3 consecutive trading days of August 6, August 7, and August 10, 2026, which is an abnormal fluctuation. After self-inspection, the company, controlling shareholders, and actual controllers have no important information that should be disclosed and not disclosed. Currently, production and operation are normal. Revenue for the year 2025 was 146.4395 million yuan, up 14.80% year on year, with a net loss of 77.7834 million yuan; revenue for the first quarter of 2026 was 37.2467 million yuan, up 11.37% year on year, with a net loss of 10.644 million yuan. The operating scale is small and there is a risk of loss, reminding investors to pay attention to transaction risks.

According to the offshore protein announcement, the daily closing price increase deviation value of the company's stock exceeded 30% during the 3 consecutive trading days of August 6, August 7, and August 10, 2026, which is an abnormal fluctuation. After self-inspection, the company, controlling shareholders, and actual controllers have no important information that should be disclosed and not disclosed. Currently, production and operation are normal. Revenue for the year 2025 was 146.4395 million yuan, up 14.80% year on year, with a net loss of 77.7834 million yuan; revenue for the first quarter of 2026 was 37.2467 million yuan, up 11.37% year on year, with a net loss of 10.644 million yuan. The operating scale is small and there is a risk of loss, reminding investors to pay attention to transaction risks.